Acorda Therapeutics prices offering at $18.50/shr

(Reuters) - Acorda intends to use the net proceeds from this offering to complete the second late stage trial of its multiple sclerosis drug, Fampridine-SR, the drug maker said in a statement.






Read more at Reuters.com Mergers News